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Abstract
Background: This study assessed the impact of closed suction drains and evaluated whether the
intraoperative use of a fibrin sealant decreased time to drain removal and wound complications in
melanoma patients undergoing inguino-femoral lymph node dissection.
Methods: A pilot study (n = 18) assessed the impact of a closed suction drain following inguino-
femoral lymph node dissection. A single-institution, prospective trial was then performed in which
patients were randomized to a group that received intraoperative application of a fibrin sealant
following inguino-femoral lymph node dissection or to a control group that did not receive sealant.
Results:  The majority of the patients enrolled felt the drains caused moderate or severe
discomfort and difficulties with activities of daily living. Thirty patients were then randomized; the
median time to drain removal in the control group (n = 14) was 30 days (range, 13–74) compared
to 29 days (range, 11–45) in the fibrin sealant group (n = 16; P  = 0.6). Major and minor
complications were similar in the two groups.
Conclusion:  Postoperative closed suction drains were associated with major patient
inconvenience. Applying a fibrin sealant at the time of inguino-femoral lymph node dissection in
melanoma patients did not reduce the time to drain removal or postoperative morbidity.
Alternative strategies are needed.
Background
Therapeutic inguino-femoral lymph node dissection
(ILND) has been associated with clinically significant
postoperative morbidities [1-3], including infections, skin
flap complications, and lower extremity lymphedema,
leading to extended hospitalizations, reduced quality of
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life, and delayed return to normal activities [4,5]. A 50%
incidence of complications following ILND in melanoma
patients has been reported, and some studies have indi-
cated that the incidence of short-term (within 30 days of
surgery) and long-term morbidity from ILND may be as
high as 75% [4-7]. Patients who have comorbidities that
compromise their ability to walk, patients who have had
complicated incisions for previous operations, obese
patients, or patients who have locally advanced disease
may experience even higher rates of postoperative mor-
bidity. Despite these risks, therapeutic lymphadenectomy
is generally performed for patients with confirmed node-
positive stage III melanoma because it is the only poten-
tially curative treatment.
Currently, closed suction drains (CSDs) are inserted at the
time of ILND to decrease seroma formation, wound
dehiscence, and infection. However, CSDs are not without
consequence: they require a high level of maintenance,
cause discomfort, interfere with mobility, and serve as
potential routes for infection when drainage is prolonged.
Therefore, strategies that can be used to prevent postoper-
ative fluid accumulation, thereby reducing the length of
time CSDs are in place or even eliminating the use of the
drains, potentially will decrease morbidity and increase
the quality of life of patients undergoing ILND for
melanoma.
One such strategy may be the use of fibrin sealants, which
have been used to provide hemostasis as well as tissue
apposition and sealing in a wide variety of surgical appli-
cations including reconstructive, breast, cardiac, gastroin-
testinal, and head and neck procedures [8]. While the role
of fibrin sealants as hemostatic agents has been well doc-
umented [9-11], these substances' ability to reduce fluid
accumulation in dissected spaces through tissue adhesion
remains unknown. Several mechanisms have been pro-
posed such as the prevention of seromas by sealing open
lymphatic channels and adherence of the elevated skin
flaps to eliminate surgically created dead spaces [12]. TIS-
SEEL® VH Fibrin Sealant (Baxter Healthcare Corporation,
Westlake Village, CA) is a fibrin sealant composed of
fibrinogen/factor XIII and thrombin. When the two sub-
stances are combined with calcium chloride and applied
topically, they produce a fibrin matrix that promotes
hemostasis by mimicking the last step of the physiological
coagulation cascade [13] and tissue adhesion by stimulat-
ing the exudative phase of wound healing [14].
We postulated that applying a fibrin sealant, such as TIS-
SEEL, in patients undergoing ILND for melanoma might
decrease the time needed for CSDs, thereby reducing the
incidence of postoperative complications and subse-
quently improving patient comfort. The primary objective
of the study was to determine whether the use of a fibrin
sealant applied to the operative bed following ILND
would result in earlier postoperative drain removal. The
secondary objectives were to determine the postoperative
morbidity associated with fibrin sealant following ILND
and to assess patient valuation of outcomes by perform-
ing a cost-benefit analysis using a willingness-to-pay
model.
Methods
Prior to the accrual of patients for the randomized study,
a pilot study was performed to assess the patient-reported
impact of a CSD following ILND. A survey was given to a
group of 18 patients who had undergone ILND at The
University of Texas M. D. Anderson Cancer Center within
the 6 preceding months. The survey focused on short-term
lifestyle changes, aversion behaviors, and expenditures
related to having a CSD. Patients were asked to judge the
drain's effect on their daily activities on a scale of 1–5,
with 1 being "not a problem" and 5 being "a severe prob-
lem." The survey also presented patients with several
hypothetical scenarios and asked patients to value, in dol-
lars, their willingness-to-pay for potential reductions in
the time to drain removal using standard methods
[15,16].
Patients
Following the pilot study, we performed a single-institu-
tion, phase III randomized trial. Approval from M. D.
Anderson's Institutional Review Board was obtained prior
to patient recruitment. Written informed consent was
obtained. Patients were eligible for the study if they were
scheduled to undergo a superficial ILND with or without
a concurrent deep pelvic (iliac/obturator) lymph node
dissection or limb perfusion for the treatment of
melanoma. Patients were not eligible if they had known
hypersensitivity to bovine proteins, had received prior
radiation therapy to the operative site, were pregnant or
lactating, had been steroid-dependent within the past 6
months, used aspirin or other anti-platelet drugs (exclud-
ing celecoxib) within 7 days of the operation, or had pre-
existing lymphoma or other pre-existing medical condi-
tions as per the discretion of the principal investigator.
Technique of lymph node dissection
With the patient positioned in a slight frog-leg position a
reverse lazy S incision is made medial to the anterior supe-
rior iliac spine extending vertically to the inguinal crease,
across the inguinal region, and then vertically down to the
apex of the femoral triangle. If a previous biopsy was per-
formed or if palpable disease is present, an ellipse of skin
incorporating the previous incision or overlying the pal-
pable disease is included. The borders of flap dissection
include the pubic tubercle and the midbody of the adduc-
tor longus medially, the lateral edge of the sartorius later-
ally, and the apex of the femoral triangle inferiorly. AllWorld Journal of Surgical Oncology 2008, 6:63 http://www.wjso.com/content/6/1/63
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fatty, node bearing tissue is removed and the saphenous
vein is divided at the apex of the femoral triangle. Dissec-
tion is maintained in the plane of the femoral vessels up
to the level of the fossa ovalis. The saphenous vein is
suture-ligated at the saphenofemoral junction and the
specimen is removed. A frozen-section examination is
performed of the lowest iliac node (Cloquet's node). The
saphenous vein can be spared in the presence of minimal
disease but should be taken in the presence of gross dis-
ease in close proximity to or surrounding the vein.
In many cases, especially in obese patients or those with
bulky disease, a sartorius muscle transposition is per-
formed by dividing the sartorius muscle at its origin on
the anterior superior iliac spine. The muscle is then dis-
sected from its anatomic position preserving the medial
vascular bundle and then transposing the muscle over the
femoral vessels. Before closure, the skin edges are critically
assessed and debrided back to healthy tissue. One or two
19F Blake drains are placed and the incision is closed in a
layered fashion with an interrupted dermal layer of
absorbable suture and then either staples or an absorbable
subcutaneous suture for the skin. Indications for a deep
groin dissection (iliac and obturator nodes) include: met-
astatic disease to Cloquet's node, clinically palpable dis-
ease, bulky or suspicious appearing pelvic
lymphadenopathy on cross-sectional imaging, or biopsy
proven deep inguinal lymph nodes.
Randomization
Participants were randomized in the operating room
using the institutional computerized randomization proc-
ess. The treatment group received TISSEEL fibrin sealant
following ILND, while the control group did not receive
fibrin sealant. The results of the randomization were
blinded until the surgical dissection was complete.
Surgical care
After ILND, while patients were still under general
anesthesia, TISSEEL (Baxter) was reconstituted according
to the manufacturer's instructions and applied locally.
Because thrombin concentration determines the setting
time of the TISSEEL clot, a diluted thrombin mixture (5
IU/mL) was used to extend this setting time; this was
made by diluting the standard preparation of 500 IU/mL
with 100 mL of sterile water and 2 mL of 10% calcium
chloride. Five milliliters of the diluted thrombin mixture
were applied to all of the cavity surfaces. A 19-French
Blake drain was inserted through a separate incision site
and surgically secured to the skin in all patients. The sur-
gical incision was then closed.
All patients were given the same postoperative instruc-
tions, including directions to minimize activity of the
involved extremity and permission to shower after 48
hours. The drain was removed once the cumulative serous
volume was ≤ 30 mL/24 hours for 2 consecutive days or if
30 days had elapsed since surgery. Patient follow-up was
performed at the M. D. Anderson Melanoma and Skin
Center or by the patients' primary physicians at 2–4 weeks
and again at approximately 6 weeks following surgery. If
patients were seen by their primary physicians, clinical
information was obtained by the research nurse by tele-
phone.
Clinical and pathological data
Clinical and pathologic data were collected prospectively
beginning at the time of enrollment until 8 weeks postop-
eratively. These data included age, sex, height, weight,
comorbidities, medications, tobacco use, previous treat-
ments for melanoma, indications for ILND, perioperative
antibiotics, type of surgical procedure, estimated blood
loss, operative time, final pathologic findings, length of
time before drain removal, and complications. Major
complications were defined as those that required hospi-
tal readmission, intravenous antibiotics, or operative deb-
ridement. Minor complications included erythema that
resolved with oral antibiotics, wound dehiscence that
could be managed on an outpatient basis, clinically rele-
vant seromas (requiring subsequent drainage), and drain-
related problems that required a visit to the clinic or emer-
gency room. A wound infection was defined as a culture-
positive seroma aspiration or clinical evidence of infec-
tion (such as fever, erythema, or cellulitis), as judged by a
clinician, that required antibiotics or more aggressive
wound management.
Statistical analysis
The primary outcome measure of the study was the time
to drain removal. The study size was determined based on
institutional experience that without fibrin glue, the
median time to drain removal was 21 days. To detect a 7-
day decrease in the time to drain removal, we calculated
that at least 28 patients needed to be enrolled in the study.
Two-sample comparisons were done using t-tests or Wil-
coxon rank sum tests for continuous variables and chi
square tests for discrete variables [17]. Univariate analyses
were performed using linear regression models to identify
any factors associated with an increased number of days to
drain removal. A log transformation was required to nor-
malize the data (days to drain removal). Computations
were carried out with Stata software (Stata/SE version 10
for Windows; StataCorp, College Station, TX). A P-value
of less than 0.05 was considered statistically significant.
Results
The 18 pilot study patients' responses to the willingness-
to-pay survey are summarized in Table 1. The median
length of time before postoperative drains were removedWorld Journal of Surgical Oncology 2008, 6:63 http://www.wjso.com/content/6/1/63
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was 20.5 days. Drain care took more than 30 minutes each
day for 72% of patients, with an overall median time of 60
minutes. The majority of patients felt the drains caused
moderate to severe discomfort (56%) as well as moderate
to severe difficulties with daily activities including dress-
ing (67%), bathing (78%), and sleeping (72%). The will-
ingness-to-pay questionnaire showed that patients were
willing to pay a median of $175 out-of-pocket for a reduc-
tion in drain time of 4 days. Five patients (28%) were will-
ing to pay $500 for a reduction in drain time.
Thirty patients were enrolled in the randomized trial
between June 17, 2005, and May 30, 2007; 14 patients
were randomized to the control group and 16 to the fibrin
sealant group. Patient demographics, comorbidities, and
preoperative treatment regimens were similar in the two
groups (Table 2). More patients in the fibrin sealant group
(n = 7) underwent deep pelvic node dissection than in the
control group (n = 3), but the difference was not signifi-
cant. The median length of surgery, estimated blood loss,
number of lymph nodes removed, and number of positive
Table 1: Summary of Responses from 18 Melanoma Patients Who Had Previous Inguino-femoral Lymph Node Dissection (ILND)
Variable No.
Median age, years (range) 56.3 (42–84)
Sex, male/female, no. patients 9/9
Median time to postoperative drain removal, days (range) 20.5 (5–35)
Time of daily care for draina, minutes (range) 60 (10–120)
No. patients with WTPa = $100 15
No. patients with WTPa = $500 5
WTPa, dollars (range) 175 (0–550)
No. of patients % of total % of patients ≥ 3
Discomfort 56
1 = Not a problem 4 22
2 = Mild problem 4 22
3 = Moderate problem 7 39
4 = Moderately severe problem 2 11
5 = Severe problem 1 6
Getting dressed 67
1 = Not a problem 3 17
2 = Mild problem 3 17
3 = Moderate problem 4 22
4 = Moderately severe problem 6 33
5 = Severe problem 2 11
Bathing 78
1 = Not a problem 3 17
2 = Mild problem 1 6
3 = Moderate problem 8 44
4 = Moderately severe problem 1 6
5 = Severe problem 5 28
Sleeping 72
1 = Not a problem 5 28
2 = Mild problem 0 0
3 = Moderate problem 7 39
4 = Moderately severe problem 4 22
5 = Severe problem 2 11
Importance of reducing number of days that drain in place 61
1 = Not at all important 4 22
2 = Slightly important 3 17
3 = Moderately important 4 22
4 = Very important 6 33
5 = Critically important 1 6
aWTP, Willingness-to pay with out-of pocket dollars for a reduction in drain time of 4 days.World Journal of Surgical Oncology 2008, 6:63 http://www.wjso.com/content/6/1/63
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lymph nodes did not differ between the two groups (Table
3).
Postoperatively, there was no statistically significant dif-
ference in the time to drain removal between the two
groups: the fibrin sealant group required drains for a
median of 31 days (range, 11–45 days), compared to 26
days (range, 13–74 days) in the control group (P = 0.6).
There was also no significant difference between the
groups with respect to overall complications. Three
patients in each group had postoperative seromas; except
for one seroma in a control-group patient, the seromas
required drainage. The incidences of wound infections
and wound dehiscence were similar in the two groups.
One patient in each group was treated with outpatient
wound vacuum placement following wound dehiscence.
Six patients (20%; two in the control group and four in
the fibrin sealant group) had major complications requir-
ing hospital readmission, intravenous antibiotics, or oper-
ative debridement. Minor complications, including
wound infection (36% in the control arm and 25% in the
fibrin sealant arm), minor wound dehiscence (36% and
38%), and drain issues (21% and 6%), were also similar
in the two groups.
There were three drain complications in the control
group: two required visits to the emergency center or out-
patient clinic, and one required placement of an addi-
tional drain. One patient in the fibrin sealant group had a
drain complication that required additional outpatient
clinic visits and placement of an additional drain.
Because there were no significant differences between the
fibrin sealant group and the control group, the groups
were combined for a univariate analysis to evaluate the
association between various clinicopathologic and treat-
ment factors and the time to drain removal. There was no
association between patient factors (i.e., body mass index
or comorbidities), prior systemic therapy, surgical treat-
ment, or postoperative complications and the time to
drain removal (Table 4).
Discussion
The results of the pilot study demonstrated that postoper-
ative CSDs had a major negative impact on patients' daily
activities, comfort, and time. In a theoretical scenario, the
majority of patients in the pilot study were willing to pay
$100–$200 out-of-pocket to reduce the time to drain
removal by at least 4 days. Given these findings, a rand-
omized controlled trial was performed using fibrin seal-
ant at the time of ILND to potentially decrease seroma
formation and the time to CSD removal. The randomiza-
tion process was successful with a similar distribution of
clinicopathologic factors among the fibrin sealant group
and the control group. Our findings, however, do not sup-
port the use of a fibrin sealant for this purpose, as it did
Table 2: Demographic and Clinicopathologic Factors in Melanoma Patients Undergoing Inguino-femoral Lymph Node Dissection 
(ILND)
Fibrin sealant group, n = 16 Control group, n = 14
Variable No.a % of total No.a % of total P value
Median age, years (range) 52 (38–91) 60 (18–73) 0.79
Sex, male/female 12/4 75/25 7/7 50/50 0.16
Median BMI, kg/m2 (range) 28.3 (19.6–42.1) 32.3 (21–48.6) 0.15
Comorbidities
Tobacco use 1 6 2 14 0.58
Diabetes 1 6 4 29 0.16
AJCC tumor stage 1.00
III 14 88 13 93
IV 2 12 1 7
Melanoma treatment prior to ILND
Surgery 0.34
None/FNA 5 31 4 29
SLN biopsy 6 38 8 57
Excisional biopsy/WLE 5 31 2 14
Systemic therapy 0.27
Chemotherapy 2 12 0 0.48
Interferon 1 6 2 14 0.59
Interleukin-2 1 6 0 1.00
BMI, body mass index; AJCC, American Joint Committee on Cancer; FNA, fine needle aspiration; SLN, sentinel lymph node; WLE, wide local 
excision.
aData are number of patients unless otherwise indicated.World Journal of Surgical Oncology 2008, 6:63 http://www.wjso.com/content/6/1/63
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not affect the time to drain removal for melanoma
patients undergoing ILND.
The pathophysiology of seroma formation has not fully
been delineated. The majority of literature pertains to
breast cancer patients undergoing mastectomy with or
without axillary lymph node dissection. In these patients,
it has been suggested that a number of anatomical factors
play a role in seroma formation including the creation of
a large potential dead space, irregularity of the chest wall,
and movement of the chest wall secondary to respiration
and shoulder movement all of which may prevent flap
Table 3: Surgical Treatments and Outcomes after Inguino-femoral Lymph Node Dissection (ILND)
Fibrin sealant group n = 16 Control group n = 14
Variable No. % of total No. % of total P value
Surgical Treatment
Patients undergoing superficial ILND 9 56 11 79 0.26
Patients undergoing superficial + deep ILND 7 44 3 21
Median length of surgery, minutes (range) 227 
(95–455)
261 
(96–713)
0.53
Median estimated blood loss, mL (range) 50 
(0–300)
75 
(0–1075)
0.75
Median No. lymph nodes removed (range) 17.5 
(9–56)
15 
(9–38)
0.07
Median No. positive lymph nodes (range) 3 
(1–12)
2 
(0–21)
0.41
Patients undergoing concurrent limb perfusion 0 0 2 14 0.21
Outcomes
Median time to drain removal, days (range) 31 
(11–45)
26 
(13–74)
0.59
Patients with clinically evident seroma 3 19 3 21 1.00
Patients with clinically evident seroma requiring drainage 3 19 2 14 1.00
Patients with wound infection 7 44 7 50 0.73
Major (inpatient management) 3 19 2 14 1.00
Minor (outpatient management) 4 25 5 36 0.69
Patients with wound dehiscence 7 44 5 36 0.65
Major (inpatient management) 1 6 0 0 1.00
Minor (outpatient management) 6 38 5 36 0.92
Patients with drain issues
No., number 1 6 3 21 0.32
Table 4: Univariate Analysis of Potential Factors Associated with Increased Time to Drain Removal Following Inguino-femoral Lymph 
Node Dissection (ILND)a
Variable Regression Coefficient Standard error P-value
Median BMI 0.01 0.01 0.37
Comorbidity
Tobacco use -0.03 0.24 0.90
Diabetes 0.04 0.20 0.86
Prior systemic therapy -0.05 0.18 0.80
Treatment group (fibrin sealant versus control) 3.31 0.11 0.88
Type of surgery (superficial +/- deep pelvic ILND) -0.01 0.16 0.95
Total no. of lymph nodes removed (< 17 versus ≥ 17) -0.15 0.14 0.32
No. of positive lymph nodes (< 2 versus ≥ 2) 0.01 0.15 0.95
Wound infection
Major -0.02 0.20 0.94
Major plus minor 0.01 0.15 0.95
BMI, body mass index; ILND, inguino-femoral lymph nodeWorld Journal of Surgical Oncology 2008, 6:63 http://www.wjso.com/content/6/1/63
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adherence [18]. Leakage from transected lymphatics is
believed to be an important factor in seroma formation
although this is supported by only scant evidence. Other
studies have suggested that seroma formation may result
from an inflammatory exudate [19,20].
Kuroi et al., have identified several risk factors for seroma
formation in breast cancer patients including obesity,
extended radical mastectomy, and large output drain vol-
ume in the early postoperative period [21]. Others have
found that thermal trauma from electrocautery dissection
may increase the incidence of seroma formation, how-
ever, alternative techniques such as sharp dissection or
ultrasonic scissors may increase operative blood loss [22].
Another surgical technique that may decrease seroma for-
mation is obliteration of the dead space by suture flap fix-
ation although this technique is not widely used [23,24].
Fibrin tissue adhesives, which first became commercially
available in Europe in 1978, have been used in numerous
surgical procedures [9-11]. To our knowledge, this is the
first published prospective trial to assess the benefit of
fibrin sealant as a means of decreasing lymphatic drainage
in melanoma patients undergoing ILND. The basis for the
current study included several studies that used fibrin tis-
sue adhesives in axillary lymph node dissection or modi-
fied radical mastectomy for breast cancer [25-30]. Given
the technical similarities between these procedures and
ILND–all of which include the creation of large skin flaps,
transaction of multiple small blood vessels and lymphat-
ics, and an anatomical area at risk for shearing forces–we
postulated that the proposed benefits of using fibrin tissue
adhesives following axillary surgery would translate to
ILND.
Although a number of studies have used fibrin tissue
adhesive following breast and axillary surgery, the results
have been inconsistent. Several randomized trials have
reported a benefit of using fibrin tissue adhesives in axil-
lary lymph node dissection or modified radical mastec-
tomy for breast cancer [26,31-34]. However, a similar
number of prospective randomized trials have reported
that fibrin sealants are ineffective at preventing seroma
formation, decreasing the time to drain removal, or reduc-
ing costs in patients undergoing breast procedures [27-
30]. Recently, Carless et al. performed a meta-analysis of
11 trials that had used fibrin sealant to prevent seroma
formation after breast cancer surgery and found that fibrin
sealant did not reduce the rate of postoperative seroma,
drainage volume, or length of hospital stay [35]. These
findings are similar to ours.
There are several limitations to the current study. First, the
study was small, including a total of only 30 patients,
which was 80 percent powered to detect a 7 day difference
in time-to-drain removal. Second, it is possible that the
amount of fibrin sealant applied or the concentration
used in this study was not optimal for lymphatic sealing.
Several factors, including safety issues and cost, must be
considered when using fibrin sealants. The fibrinogen and
thrombin components of TISSEEL are obtained from
pooled human plasma from screened donors [8] and thus
carries a risk of viral transmission. To avert this risk, a dou-
ble-vapor heat deactivation procedure is used to eliminate
viruses, and polymerase chain reaction testing for viral
deoxyribonucleic acid is performed [8,13]. Another safety
concern in TISSEEL is that aprotinin, the antifibrinolytic
component used to prevent sealant degradation, is from a
bovine source, and thus the product is contraindicated in
patients who are sensitive to bovine products [36]. Newer,
synthetic fibrin sealants have been developed to avoid the
risk of allergic reactions. Another promising application
of fibrin sealant matrices is the addition of products such
as antibiotics or antineoplastics that would allow the
fibrin sealant to act as a medium for local delivery of these
agents [13,34].
Conclusion
The application of a fibrin sealant at the time of ILND in
patients with melanoma does not significantly influence
the time to drain removal, seroma formation, or subse-
quent postoperative morbidity. Based on the results of
this study, the use of fibrin sealant for ILND is not indi-
cated. Alternative strategies that decrease the time to drain
removal or eliminate the use of CSDs would be valuable
in improving the quality of life of melanoma patients
undergoing ILND.
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